Papers 13423
1 page of 1,343 pages (13.4k results)
#1Mina Lobbous (UAB: University of Alabama at Birmingham)
#2L. Burt Nabors (UAB: University of Alabama at Birmingham)H-Index: 39
#1Raymond Y. Huang (Brigham and Women's Hospital)H-Index: 20
#2Jeffrey P. Guenette (Brigham and Women's Hospital)H-Index: 6
#1Robert SiddawayH-Index: 1
#2Cynthia Hawkins (U of T: University of Toronto)H-Index: 58
#1Rupesh Kotecha (Baptist Hospital of Miami)H-Index: 1
#1Rupesh Kotecha (Baptist Hospital of Miami)H-Index: 13
Last. Muni Rubens (Baptist Hospital of Miami)H-Index: 2
view all 13 authors...
BACKGROUND: This systematic review reports on outcomes and toxicities following stereotactic radiosurgery (SRS) for non-functioning pituitary adenomas (NFAs) and presents consensus opinions regarding appropriate patient management. METHODS: Using the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses, a systematic review was performed from articles of >/=10 patients with NFAs published prior to May 2018 from the Medline database using the key words "radiosurgery...
#1Niels VerburgH-Index: 4
#1Niels Verburg (UvA: University of Amsterdam)H-Index: 1
Last. Philip C. De Witt HamerH-Index: 19
view all 16 authors...
BACKGROUND: Surgical resection and irradiation of diffuse glioma are guided by standard MRI: T2/FLAIR-weighted MRI for non-enhancing and T1-weighted gadolinium-enhanced (T1G) MRI for enhancing gliomas. Amino acid PET has been suggested as new standard. Imaging combinations may improve standard MRI and amino acid PET. The aim of the study was to determine the accuracy of imaging combinations to detect glioma infiltration. METHODS: We included 20 consecutive adults with newly-diagnosed non-enhanci...
2 CitationsSource
#1Masaki Terabe (NIH: National Institutes of Health)H-Index: 37
Last. Mark R. GilbertH-Index: 65
view all 2 authors...
#1Timothy J. Kaufmann (Mayo Clinic)H-Index: 26
#2Bradley J. Erickson (Mayo Clinic)H-Index: 32
#1Maren Cam (Nationwide Children's Hospital)H-Index: 3
#2Manish Charan (Nationwide Children's Hospital)H-Index: 1
Last. Hakan Cam (OSU: Ohio State University)H-Index: 6
view all 14 authors...
BACKGROUND: Glioblastoma (GBM) remains one of the least successfully treated cancers. It is essential to understand the basic biology of this lethal disease and investigate novel pharmacological targets to treat GBM. The aims of this study were to determine the biological consequences of elevated expression of DeltaNp73, an N-terminal truncated isoform of TP73, and to evaluate targeting of its downstream mediators, the angiopoietin 1 (ANGPT1)/tunica interna endothelial cell kinase 2 (Tie2) axis,...
1 CitationsSource
#1Connor J. Liu (WashU: Washington University in St. Louis)H-Index: 4
#2Maximilian Schaettler (WashU: Washington University in St. Louis)
Last. Tanner M. Johanns (WashU: Washington University in St. Louis)H-Index: 13
view all 11 authors...
BACKGROUND: Although clinical trials testing immunotherapies in glioblastoma (GBM) have yielded mixed results, new strategies targeting tumor-specific somatic coding mutations, termed neoantigens, represent promising therapeutic approaches. We characterized the microenvironment and neoantigen landscape of the aggressive CT2A GBM model in order to develop a platform to test combination checkpoint blockade and neoantigen vaccination. METHODS: Flow cytometric analysis was performed on intracranial ...
#1Karl-Josef Langen (RWTH Aachen University)H-Index: 42
#2Norbert Galldiks (University of Cologne)H-Index: 25
Last. Philipp LohmannH-Index: 9
view all 3 authors...
Top fields of study
Cancer research